August 21, 2019
Don’t question your logic … as to your continued investot complacency versus trader's sandbox antics
Liquidity remains a cause for concern
A looking for a few bounces to the upside but, again who and where are the buyers?
August 19, 2019
Share pricing is down -$0.01 to $0.98
Pricing of $57.5 M offering of preferred stock and warrants and entry into concurrent Private Placement of up to $70 MM and $12.1 M "Upfront Option Fee"
... SELL
August 20, 2019
Monday, I stated to SELL into strength worried about pricing’s sustainability
Pre-open indications: 6 HITs and 3 MISS <I’m sticking by my two (2) undervalued>
What’s wrong with be right so often?
“Venimus nos emit et vendidit nos rursus” – “We have bought and sold again". That's why today's not a good day for all who owned cell and gene therapy equities to reassess?
August 5, 2019
A scorecard of earnings of 45 covered companies The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"
August 5, 2019
Volatility, algorithms, sustainability … but, geopolitical ssues are "trumping" the news Add to the list, trend analysis, momentum’s magnitude, technicals and fundamentals – do they indicate expected pricing performance in 2019? Why spend time finding sector news and analytics … it’s all right here! News has become "something" sold into
May 19, 2019
A scorecard of earnings of 45 covered companies 41 so far: 2 acquired (AST, OSIR) 1 on acquisition hold - ONCE) and 1 set to be reversed (HSGX) ... The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
